Full text is available at the source.
Activation of Rev-erbα attenuates lipopolysaccharide-induced inflammatory reactions in human endometrial stroma cells via suppressing TLR4-regulated NF-κB activation
Activating Rev-erbα reduces inflammation caused by bacterial toxins in human uterine support cells by blocking a key immune signaling pathway
AI simplified
Abstract
LPS treatment increased mRNA levels of pro-inflammatory cytokines in human endometrial stroma cells (hESCs).
- Rev-erbα plays a key role in regulating the balance between pro-inflammatory and anti-inflammatory responses in cells.
- Pharmacological activation of Rev-erbα using SR9009 significantly reduced the production of pro-inflammatory cytokines in hESCs treated with LPS.
- Knockdown of Rev-erbα led to increased levels of IL-1β, IL-6, and IL-8, along with elevated expression of the core clock gene Bmal1.
- SR9009 inhibited the expression of toll-like receptor 4 (TLR4) and the activation of NF-κB, which were induced by LPS treatment.
- These findings suggest that activating Rev-erbα may help mitigate inflammation in hESCs.
AI simplified